A new era for Nuclear Medicine neuroimaging in Spain: Where do we start from in Spain?
Balsa MA (1), Camacho V (2), Garrastachu P (3), García-Solís D (4), Gómez-Río M (5), Rubí S (6), Setoain X (7), Arbizu J (8); por el Grupo de Neuroimagen SEMNIM.
(1) Servicio de Medicina Nuclear, Hospital Universitario de Getafe, Madrid, España.
(2) Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau i Universitat Autònoma de Barcelona , Barcelona, España.
(3) Servicio de Medicina Nuclear, Hospital San Pedro y Centro de Investigación Biomédica de la Rioja (CIBIR), Logroño, España.
(4) Servicio de Medicina Nuclear, Hospital Universtario Virgen del Rocío, Sevilla, España.
(5) Servicio de Medicina Nuclear, Complejo Hospitalario Universitario de Granada (CHGRA) e Instituto de Investigación Biosanitaria Granada (IBS), Granada, España.
(6) Servicio de Medicina Nuclear, Hospital Universitari Son Espases e Instituto de Investigación Sanitaria de Palma, Palma, España.
(7) Servicio de Medicina Nuclear, Hospital Clínic de Barcelona, Barcelona, España.
(8) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Pamplona, España.
To determine the status of neuroimaging studies of Nuclear Medicine in Spain during 2013 and first quarter of 2014, in order to define the activities of the neuroimaging group of the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM).
MATERIAL AND METHODS:
A questionnaire of 14 questions was designed, divided into 3 parts: characteristics of the departments (equipment and professionals involved); type of scans and clinical indications; and evaluation methods. The questionnaire was sent to 166 Nuclear Medicine departments.
A total of 54 departments distributed among all regions completed the questionnaire. Most departments performed between 300 and 800 neuroimaging examinations per year, representing more than 25 scans per month. The average pieces of equipment were three; half of the departments had a PET/CT scanner and SPECT/CT equipment.
Scans performed more frequently were brain SPECT with 123I-FP-CIT, followed by brain perfusion SPECT and PET with 18F-FDG. The most frequent clinical indications were cognitive impairment followed by movement disorders. For evaluation of the images most sites used only visual assessment, and for the quantitative assessment the most used was quantification by region of interest.
These results reflect the clinical activity of 2013 and first quarter of 2014. The main indications of the studies were cognitive impairment and movement disorders. Variability in the evaluation of the studies is among the challenges that will be faced in the coming years.
CITATION Rev Esp Med Nucl Imagen Mol. 2017 Feb 22. pii: S2253-654X(16)30190-1. doi: 10.1016/j.remn.2016.12.004